Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.

Revenue
+12.3%
EPS
−6.24%
Free cash flow
−29.4%
Total debt
−11.5%

Quarter to September 2026, against a year earlier

33.04 0.57 +1.76%
Market cap
$1.9B
P/E
10.7×
Fwd P/E
9.9×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

5 4 4 4
ROE
20.75% 17.86% 20.46% 18.73%
ROA
13.98% 12.51% 14.61% 13.30%
ROIC
50.40% 27.66% 29.70% 30.45%
Return on Tangible Assets
24.23% 25.93% 31.24% 26.93%
Average Days of Receivables
40.68 43.93 42.21 47.13
Free Cash Flow per Share
6.05 5.91 6.13 5.53
Free Cash Flow
347.89 341.97 355.08 323.04
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026